Patent US5755226A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5755226A Expired / Lapsed US ⏱️ 0.0 years remaining

Method and apparatus for noninvasive prediction of hematocrit

Assignee: Terumo Cardiovascular Systems Corp
•
Filing: 1996-09-10
•
Granted: 1998-05-26
•
Expires: 2016-09-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method and apparatus for the direct noninvasive prediction of hematocrit in mammalian blood using photoplethysmography techniques and data processing. The method and apparatus also include optional prediction of other analytes of interest: percent oxygen saturation of mammalian blood and methemoglobin of stored blood. The method and apparatus can be used for the immediate, periodic, or continuous noninvasive diagnosis or monitoring of hematocrit levels in mammalian patients without pain to the patient or exposure of the health care practitioner to the blood of the patient.

Inventors

  • 👤 Hatim M. Carim
  • 👤 Orlin B. Knudson
  • 👤 Bruce P. Ekholm
  • 👤 David P. Erickson
  • 👤 William J. Kelliher, Jr.
  • 👤 Michael J. Rude

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 22:18
CPC Classifications
A; A61; A61B; A61B5/00; A61B5/145; A61B5/1455; A61B5/14551; A61B5/14552; A61B5/14535; A61B5/68; A61B5/6801; A61B5/6843; A61B5/72; A61B5/7228; G; G01; G01N; G01N21/00; G01N21/17; G01N21/25; G01N21/31; G01N21/314; G01N21/35; G01N21/359; A61B2562/00; A61B2562/02; A61B2562/0233; A61B2562/04; A61B2562/046; A61B5/7235; A61B5/7239; Y; Y10; Y10S; Y10S977/00; Y10S977/902; Y10S977/904; Y10S977/905

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 314 words
An apparatus for the noninvasive prediction of hematocrit within mammalian tissue, comprising: (a) a light source adapted to noninvasively interrogate the mammalian tissue with light of at least two wavelengths, wherein the at least two wavelengths are selected according to wavelength selection criteria, and wherein the wavelength selection criteria comprise: (1) a wavelength where absorbance of water is at or near a measurable peak; (2) at least one wavelength where absorbance of oxyhemoglobin and deoxyhemoglobin are predictable and represent total hemoglobin content; (3) a wavelength where the absorbance of water greatly exceeds the absorbance of all forms of hemoglobin; and (4) a wavelength where the absorbance of all forms of hemoglobin greatly exceeds the absorbance of water; wherein each of the wavelength selection criteria must be satisfied, wherein each selected wavelength can satisfy one or more than one of the wavelength selection criteria, and wherein at least one of the selected wavelengths is in the range 1150-2100 nm; (b) at least one detector adapted to receive light of the selected wavelengths transmitted through the mammalian tissue, the detector further adapted to convert the transmitted light of each selected wavelength from optical signals into electrical signals; and (c) processing means, connected to receive the electrical signals from the detector, the processing means for: determining the intensity of at least one peak, the intensity of at least one valley, and the intensity of at least one direct current value for the transmitted light of each selected wavelength; determining at least one pseudo-absorption H Value for each selected wavelength, wherein each H Value is based on the intensities of the at least one peak, at least one valley, and the at least one direct current value; and determining a prediction equation for the noninvasive prediction of hematocrit, wherein the prediction equation is based on true hematocrit values and the pseudo-absorption H Values determined for each selected wavelength.
Claim 2
Independent Claim 314 words
An apparatus for the noninvasive prediction of hematocrit within mammalian tissue, comprising: (a) a light source adapted to noninvasively interrogate the mammalian tissue with light of at least two wavelengths, wherein the at least two wavelengths are selected according to wavelength selection criteria, and wherein the wavelength selection criteria comprise: (1) a wavelength where absorbance of water is at or near a measurable peak; (2) at least one wavelength where absorbance of oxyhemoglobin and deoxyhemoglobin are predictable and represent total hemoglobin content; (3) a wavelength where the absorbance of water greatly exceeds the absorbance of all forms of hemoglobin; and (4) a wavelength where the absorbance of all forms of hemoglobin greatly exceeds the absorbance of water; wherein each of the wavelength selection criteria must be satisfied, wherein each selected wavelength can satisfy one or more than one of the wavelength selection criteria, and wherein at least one of the selected wavelengths is in the range 1150-2100 nm; (b) at least one detector adapted to receive light of the selected wavelengths transmitted through the mammalian tissue, the detector further adapted to convert the transmitted light of each selected wavelength from optical signals into electrical signals; and (c) processing means, connected to receive the electrical signals from the detector, the processing means for: determining the intensity of at least one peak, the intensity of at least one valley, and the intensity of at least one direct current value for the transmitted light of each selected wavelength; determining at least one pseudo-absorption H Value for each selected wavelength, wherein each H Value is based on the intensities of the at least one peak, at least one valley, and the at least one direct current value; and determining a prediction equation for the noninvasive prediction of hematocrit, wherein the prediction equation is based on true hematocrit values and the pseudo-absorption H Values determined for each selected wavelength.
Claim 3
Dependent Claim 20 words
The apparatus of claim 1, wherein the processing means is further adapted for noninvasively predicting hematocrit using the prediction equation.
Claim 4
Dependent Claim 22 words
The apparatus of claim 2, further comprising: (a) means for calculating a coefficient of variation of the at least one H Value.
Claim 5
Dependent Claim 16 words
The apparatus according to claim 2, further comprising: (d) means for displaying the prediction of hematocrit.
Claim 6
Dependent Claim 14 words
The apparatus of claim 1, wherein the modulated light source maintains relative spectral intensity.
Claim 7
Dependent Claim 42 words
The apparatus according to claim 1, wherein the wavelength selection criteria further comprises: (5) a wavelength where the absorbance of oxyhemoglobin greatly exceeds the absorbance of deoxyhemoglobin; and (6) a wavelength where the absorbance of deoxyhemoglobin greatly exceeds the absorbance of oxyhemoglobin.
Claim 8
Dependent Claim 72 words
The apparatus according to claim 6, wherein the wavelength selection criteria further comprises: (7) at least one different wavelength from selection criteria (1) where the absorbance of water is at or near a measurable peak or shoulder and is subjected to differing interferences than selection criteria (1); and (8) a wavelength where the absorbance of water is in or near a valley between peaks and where the absorbance of hemoglobin is minimal.
Claim 9
Dependent Claim 25 words
The apparatus according to claim 7, wherein the wavelength selection criteria further comprises: (9) a wavelength where water and hemoglobin are in an isosbestic relationship.
Claim 10
Dependent Claim 111 words
The apparatus according to claim 8, wherein the wavelength selection criteria (1) has a range of about 1160-1230 nm; wherein the wavelength selection criteria (2) has a range of about 800-850 nm; wherein the wavelength selection criteria (3) has a range of about 1150-2100 nm; wherein the wavelength selection criteria (4) has a range of about 450-690 nm; wherein the wavelength selection criteria (5) has a range of about 650-690 nm; wherein the wavelength selection criteria (6) has a range of about 890-920 nm; wherein the wavelength selection criteria (7) has a range of about 960-990 nm; and wherein the wavelength selection criteria (8) has a range of about 1100-1120 nm.
Claim 11
Dependent Claim 20 words
The apparatus according to claim 1, further comprising a fresnel lens to shape the transmitted light of each selected wavelength.
Claim 12
Dependent Claim 25 words
The apparatus according to claim 1, further comprising a high common mode rejection amplifier for amplifying and filtering the transmitted light of each selected wavelength.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2001-05-25 2001-11-24 2002-05-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2005-05-25 2005-11-24 2006-05-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2009-05-25 2009-11-24 2010-05-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag